The c-MYB proto-oncogene encodes a transcription factor which plays an important role in hematopoiesis. We detected truncated c-MYB mRNA (2.0 kb) and c-Myb protein (55 kDa) in the TK-6 cell line, which was established from a patient with chronic myelogenous leukemia in T cell blast crisis. Mutated c-MYB cDNA clone (WTK-1) was isolated from a TK-6 cell cDNA library and sequenced in its entirety. Compared with the wildtype human c-MYB sequence, the WTK-1 sequence diverged at the 3′ ends of exons 9. A termination codon was present as the second codon downstream from the point of divergence and was followed by a previously unknown rearranged sequence. The conceptual protein encoded by WTK-1 (Myb ) comprises 402 amino acids and lacks the negative regulatory domain of the normal c-Myb, reminiscent of the activated form of Myb protein. Luciferase reporter assay in NIH3T3 cells showed that the expression vector encoding Myb TK-6 stimulated Myb-regulated mim-1 promoter more effectively than that encoding wild-type human c-Myb, suggesting that Myb TK-6 is functional as a transcription factor, and thus as a potential transforming protein. Southern blot and mutant allele-specific polymerase chain reaction analyses showed that the same rearrangement of the c-MYB gene in TK-6 was present in late, but not in early, specimens obtained from the patient, indicating that this mutation had been acquired during disease progression.
Introduction
The cellular MYB gene (c-MYB) is a proto-oncogene that encodes a nuclear DNA-binding protein with sequencespecific transactivation activity.
1 c-MYB is expressed at high levels in immature hematopoietic cells, 2 and the c-Myb protein plays an important role in growth regulation and differentiation in these cells. [3] [4] [5] Targeted disruption of the c-MYB locus in mice resulted in neonatal death due to failure of effective fetal hematopoiesis. 6 Activated forms of c-MYB have been separated from two independent chicken leukemia viruses, avian myeloblastosis virus (AMV) and E26, both of which cause leukemia in chickens and transform hematopoietic cells in vitro. 7 The v-Myb protein of AMV is truncated both at amino (N)-and carboxyl (C)-termini of c-Myb, and it also has several point mutations. That of E26 is a chimeric protein of Gag-Myb-Ets, and its Myb portion also lacks both termini. Retroviral insertion in either the 5′ or 3′ portion of the c-MYB gene, which generates Nterminally or C-terminally truncated c-Myb protein, respectively, has been shown to cause leukemia in mice. 8, 9 Furthermore, an experiment to express deletion mutants of c-Myb in chicken bone marrow cells showed that both N-terminally and C-terminally truncated c-Myb were transforming, while full-length c-Myb was not. 10 Correspondence: A Tomita, First Department of Internal Medicine, Nagoya University School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466, Japan; Fax: 81 52 744 2157 Received 2 March 1998; accepted 2 May 1998 All these data suggest that the abnormality of the c-MYB gene may well be involved in human leukemias. The expression of structurally altered c-Myb protein, however, has not been reported in human leukemias, although the overexpression of the gene has been described in hematopoietic [11] [12] [13] and non-hematopoietic 14-17 malignancies. We previously described a cell line, TK-6, which was established from the pleural effusion of a patient with chronic myelogenous leukemia (CML) in T cell blast crisis. 18 In addition to the Philadelphia (Ph) chromosome, the karyotype of this cell line shows an abnormality in the long arm of chromosome 6, on which c-MYB gene is located 19 (48, XY, ins(1;?)(q21;?), del(1)(q21q32), del(6)(q21), dic(7)(:p13→cen→q32q11.2→ cen→pter), der(9)t(9;22)(q34;q11), der(22)t(9;22;?)(q34;q11;?), +mar 1, +mar 2). 18 We found that TK-6 cells express C-terminally truncated c-Myb protein (Myb ), which has elevated transactivation activity compared to wild-type c-Myb. Furthermore, we demonstrated that this c-MYB gene abnormality had appeared during disease progression in the patient.
Materials and methods

Cell lines and culture conditions
TK-6 cells were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS). NIH3T3 cells were cultured in Dulbecco's modified Eagle's medium (GibcoBRL, Grand Island, NY, USA) containing 10% FBS for transient transfection assay. Cell lines were incubated at 37°C in a humidified atmosphere containing 5% CO 2 .
Northern and Southern blot analysis
Total RNA was extracted from TK-6, HL-60, MOLT-4 and HeLa cells by the guanidinium thiocyanate method as described previously. 20 Ten g was subjected to electrophoresis in a 1% agarose gel, and Northern hybridization was performed with 32 P-labeled 2.5-kb EcoRI fragment of human c-MYB cDNA 19 (kindly provided by Dr K Adachi, First Department of Internal Medicine, Nagoya University School of Medicine). After the first hybridization, the membrane was rehybridized with a ␤-actin cDNA probe.
High molecular weight DNA was extracted from TK-6 cells and original cells from the patient by standard techniques. 21 Genomic DNA was digested with EcoRI or SacI, the resulting fragments were separated by electrophoresis in a 1% agarose gel, and Southern hybridization was performed with 32 P-labeled 523-bp MYB TK-6 cDNA probe.
Immunoblot analysis
Cultured cells (1 × 10 7 ) were washed in phosphate-buffered saline (PBS), resuspended in 100 l of 2 × SDS sample buffer (62.5 mm Tris-HCl (pH 6.8), 2% (w/v) SDS, 10% (v/v) glycerol, 5% (v/v) 2-mercaptoethanol, 0.01% (w/v) bromophenol blue), and boiled. Portions (10 l) of the cell lysates were fractionated by SDS-polyacrylamide gel electrophoresis on a 7.5% gel, and immunoblotting was performed using rabbit antiserum to the DNA-binding domain of chicken c-Myb (kindly provided by Dr SA Ness), visualized with ECL detection kit (Amersham, Little Chalfont, UK).
Construction and screening of cDNA library
Polyadenylated RNA was isolated with Dynabeads Oligo (dT) 25 (Nihon Dynal, Tokyo, Japan) and washed thoroughly with the use of a Magnetic Particle Concentrator (Dynal MPC-E-1; Nihon Dynal), after which 5 g was used to construct a cDNA library. Reverse transcription was performed from the poly(dT) end of the XhoI linker-primer with the use of Molony murine leukemia virus reverse transcriptase in the presence of RNase inhibitor and 5-methyl dCTP. Second-strand cDNA was synthesized by DNA polymerase I in the presence of RNase H. The fill-up reaction to create a 3′ blunt end was catalyzed by recombinant Pfu DNA polymerase. EcoRI adapters were ligated to both ends of the cDNA with T4 DNA ligase; after phosphorylation by T4 polynucleotide kinase, XhoI digestion released the EcoRI adapter and residual linkerprimer from the 3′ end of the cDNA. The cDNAs were fractionated by size with Sephacryl S-500 spin columns (Pharmacia, Uppsala, Sweden) and ligated into EcoRI and XhoI sites of the Uni-ZAP XR vector (ZAP-cDNA Gigapack III Gold cloning kit; Stratagene, La Jolla, CA, USA). Phages were packaged in E. coli XL-1-Blue MRF′ grown in 150-mm petri dishes, and transferred to Hybond-N+ membranes (Amersham). The membranes were hybridized overnight at 65°C with the same 32 P-labeled c-MYB cDNA probe (ෂ4.8 × 10 7 d.p.m./ml) as that used in Northern analysis. About 2.6 × 10 6 plaque-forming units of recombinant phage were screened, and positive plaques were replated and rescreened. The pBluescript SK phagemids containing cDNA inserts were excised from the Uni-ZAP XR clones in vivo by coinfection with ExAssist helper bacteriophage in XL-1-Blue MRF′. Another E. coli strain, SOLR, containing pBluescript was grown, and the cDNA inserts of pBluescript clones were subjected to nucleotide sequence analysis.
Sequence analysis of cDNAs isolated
The nucleotide sequences of the isolated cDNAs were determined with an automated DNA sequencer (ABI Prism 310 Genetic Analyzer; Perkin-Elmer, Emeryville, CA, USA). The dye primer cycle sequencing method 22 with primers T3 (5′-AATTAACCCTCACTAAAGGG-3′) and T7 (5′-GTAAT-ACGACTCACTATAGGGC-3′) as well as the dye terminator cycle sequencing method 23 with original oligonucleotide primers (sequence data not shown) was performed with a Ready Reaction kit containing AmpliTaq DNA polymerase (PerkinElmer) and a Thermal Cycler 9600 (Perkin-Elmer). The obtained nucleotide sequences were compared with sequences in the GenBank database with the use of the BLASTN homology search program. 24 
Long polymerase chain reaction
To obtain genomic fragment of the MYB gene, long polymerase chain reaction (long-PCR) was performed. PCR primers were based on the sequence of human c-MYB cDNA previously determined 19 (sense primer; sp8: 5′-ACTATAAT-GATGAAGACCCT-3′, sp9: 5′-TGATCGTCCACCAGGGCA-3′, spX: 5′-CAGTCTTGAGGCAGCCCA-3′, anti-sense primer; asp9:
5′-CCAAACAGGAAACAGGTGC-3′, asp10: 5′-CTGGTCTCTATGAAATGGTG-3′). In addition, primer aspY (5′-GGTTACAAGGTGCTCGGTG-3′) was based on the 3′ portion of the sequence in the MYB TK-6 cDNA clone WTK-1. We used sp8-asp9 and sp9-asp10 primer pairs to amplify all of introns 8 and 9, respectively, from the wild-type allele, and sp9-aspY to amplify the genomic fragment downstream of exon 9 corresponding to the rearranged region of the mutant allele. Long-PCR was performed with an LA PCR Kit Version 2 (Takara, Otsu, Japan). Genomic DNA (50 ng) and primers were subjected to 30 cycles of denaturation for 40 s at 94°C, annealing for 30 s at 55°C, and extension for 5 min at 72°C in a Thermal Cycler 9600. The PCR products were resolved on a 1% low-melting-point agarose gel (Bio-Rad, Hercules, CA, USA), and extracted with a QIAquick Gel Extraction Kit (Qiagen, Santa Clarita, CA, USA). The sequences of long-PCR products were directly analyzed by the dye terminator cycle sequencing method described above.
Construction of expression vector and luciferase reporter assay
The open reading frames (ORF) of MYB TK-6 (WTK-1) were amplified by the long-PCR method (sense primer; 5′-GGGGTACCATTCGGCACGAGCCGCGCC-3′, anti-sense primer; 5′-GGGGGCCCAGGGTCTAGTGGGCTGCCT-3′) and cloned into KpnI/ApaI restriction endonuclease sites of pcDNA3.1 mammalian expression vector (Invitrogen, Carlsbad, CA, USA) which contained CMV promoter (pcDNA-WTK-1). The BamHI fragment of CO072 plasmid clone (provided by Health Science Research Resources Bank, Osaka, Japan), which contained 3′ part of the c-MYB gene, was inserted into the BamHI site of pcDNA-WTK-1 clone to obtain full-length c-MYB expression vector (pcDNA-c-myb). Each sequence was confirmed by direct sequencing using an ABI 310 autosequencer. The mim-1-luciferase reporter construct (mim-1-luc), which contained chicken mim-1 promoter gene, was provided by Dr SA Ness. 25 Murine fibroblast cell line NIH3T3 cells (2 × 10 5 each) were cultured in 6-cm culture dishes for transient transfection assay. Each expression construct was transfected with reporter plasmid by the calcium phosphate method, 26 cells were dissolved 48 h after transfection, and luciferase activity was measured using the PicaGene luciferase assay system (Toyo Ink Mfg. Co., Ltd, Tokyo, Japan) and LUMAT measuring instruments (Berthold, Postfach, Germany).
Mutant allele-specific PCR
The primers spX and aspY were used for mutant-allele specific PCR (MAS-PCR) 27 to detect the mutant region. The anti-sense primer asp9A (5′-CGTTTGTTCACCCTTGGGC-3′) was also designed as a control on the basis of the sequence of the alternatively spliced exon 9A to generate PCR products from wildtype c-MYB. PCR was performed for 35 cycles of denaturation for 30 s at 94°C, annealing for 30 s at 55°C, and extension for 45 s at 72°C, with 50 ng of template DNA. Two long-PCR products (described above) were used as control templates because they contained a portion of the normal or rearranged allele.
Results
Expression of c-MYB gene and protein in TK-6 cells
Because of the presence of chromosome 6q abnormality on which c-MYB gene is located, we examined expression of the c-MYB gene in TK-6 cells by Northern blot analysis. HL-60, MOLT-4, and HeLa cell genes were analyzed as controls. As previously shown, HL-60 and MOLT-4 cells contained abundant c-MYB mRNA of normal size (3.8 kb). 28, 29 In contrast, TK-6 cells showed a band of 2.0 kb but did not exhibit a transcript of the normal size (Figure 1a) . HeLa cells, which are not of hematopoietic origin, did not contain detectable c-MYB transcripts, although all the cell lines examined exhibited similar amounts of ␤-actin mRNA.
We 
Cloning and sequencing of MYB TK-6 cDNA
A TK-6 cDNA library was screened by plaque hybridization with a human c-MYB cDNA probe. We obtained six positive clones, and sequenced their inserts. Five of the six clones showed the same derivation and were designated the WTK-1 group, whereas the remaining clone, designated WTK-2, showed a different sequence. The cDNA inserts of WTK-1 and WTK-2 comprised 1750 and 570 bp, respectively. Comparison with the sequence of human MYB LMC-8 (GenBank accession No., M15024), 19 revealed that the initiation codon (ATG) and downstream sequence of WTK-1 were identical to those of MYB LMC-8 up to nucleotide position 1316 of the latter (Figure 2) . Nucleotide position 1316 of MYB LMC-8 represents the 3′ end of exon 9. 29 The schematic structure of WTK-1 is shown in Figure 3b . 9rY region depicted in Figure 3b showed 90% identity with the repetitive sequence of the human LTR7 element according to a BLASTN homology search. 24 The open reading frame (ORF) of WTK-1 closed one amino acid downstream of the position of divergence, resulting in a predicted polypeptide of 402 residues with a molecular mass of ෂ55 kDa. The sequence of WTK-2 diverged completely from that of MYB LMC-8 at nucleotide position 1062 (Figure 2a and c), and the downstream sequence was identical to the sequence of part of MYB HMYB-1 cDNA, which had been isolated from patients with acute myeloid leukemia. 30 The 3′ sequence of WTK-2 is 240 bp longer than that of MYB
The ORF of WTK-2 closed seven amino acids downstream of the position of divergence.
To determine the identity of the c-MYB transcript of abnormal size in TK-6 cells with the WTK-1 clone, we subjected the membrane from Northern analysis to rehybridization with a 9iX-specific probe (Figure 3b ). This probe detected the same 2.0-kb mRNA as the c-MYB cDNA probe (data not shown), indicating that the transcript corresponds to the WTK-1 clone. Furthermore, the predicted size of the protein encoded by WTK-1 was about 55 kDa. These results suggest that the Figure 1b) . A conceptual immunoreactive protein corresponding to the protein encoded by the WTK-2 cDNA, which is 79 amino acids shorter than that of the WTK-1-encoded protein, was not detected at the expected position, and mRNA expression corresponding to WTK-2 clone was not detected in Northern blot analysis either. We did not perform any further examination because we suspected the WTK-2 clone might have no biological significance.
Analysis of genomic structure of c-MYB gene in TK-6 cells
The genomic structure of the MYB TK-6 gene was analyzed by sequencing genomic long-PCR fragments (primer pairs; sp9-asp10 and sp9-aspY), and the result is summarized in Figure  3a . A long-PCR fragment (sp9-asp10; 3.0 kb) spanning the 3′ portion of exon 9 to the 5′ portion of exon 10 was obtained from genomic DNA of both TK-6 cells and cells of normal control individuals (data not shown). We designed the primer aspY based on a region (9rY; Figure 3b ) of the divergent sequence of WTK-1. Primers sp9 and aspY generated a 1.0-kb long-PCR fragment from TK-6 cells but not control cells (data not shown).
The 9iX (Figure 3b ) sequence (171 bp) located in the 3′ portion of WTK-1 was apparent in intron 9 of the normal MYB gene, the 9rY sequence, which is located downstream of 9iX in WTK-1, was not apparent in the normal intron 9 but was present adjacent to 9iX in the sp9-aspY genomic fragment. These data indicate that the 9iX-9rY fused region was used as a new exon in the MYB TK-6 gene. Next, a long-PCR fragment (primer pair; sp8-asp9) was analyzed. The 3′ portion of WTK-2 sequence, which diverged from the c-MYB gene at the 3′ end of exon 8, was followed by intron 8 sequence of MYB gene (8iZ region in Figure 3a) .
The exon-intron structure of the normal c-MYB and mutant 19 and the open box indicates the alternatively spliced exon 9A. 29 The shaded box labeled 9iX represents an exon sequence of the mutant gene that is present in intron 9 of the normal gene. The obliquelined box labeled 9rY represents an exon sequence present only in the mutant gene adjacent to the 3′ end of 9iX. The sequence indicated by the oblique-lined box labeled 8iZ in intron 8 of both normal and mutant genes downstream of the 3′ end of exon 8 corresponds to the 3′ sequence of WTK-2 which diverged from wild-type c-MYB gene. PCR primers are indicated by arrows: sp8, sp9 and spX (sense primers); asp9, asp9A, asp10 and aspY (anti-sense primers). The structure of the region downstream of 9rY was not determined. 
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TK-6 genes was also recognized. It appeared that the new exon of the MYB TK-6 gene (9iX-9rY) complied with the GT-AG rule of exon-intron junction (sequence data not shown).
Transactivation activity of Myb TK-6 protein
We then wished to discover whether Myb TK-6 is functional as a Myb protein. The most interesting function of Myb protein is its transforming activity. Assessment of transforming activity of Myb proteins is difficult, however, since they do not transform non-hematopoietic cells 31 and conventional focus-formation assay with fibroblasts would not be informative. The other important function of Myb proteins is regulation of transcription of certain genes, 25 which is known to correlate with transformation activity. 32 Therefore, we determined to test the transactivation activity of Myb TK-6 on the promoter of an established Myb-regulated gene, chicken mim-1. 25 We constructed plasmid mammalian expression vectors with CMV promoter that encodes wild-type c-Myb and Myb , respectively, and performed luciferase reporter assays in NIH3T3 fibroblasts. The protein production by each expression vector was confirmed by immunoblot analysis with anti-Myb polyclonal antibody (data not shown). Cotransfection of pcDNA-c-myb, which encodes wild-type human cMyb, activated mim-1 promoter about 2.5-fold over basal level with an empty vector (pcDNA) (Figure 4) . pcDNA-WTK-1, encoding Myb TK-6 , activated reporter expression 4-fold more than pcDNA-c-myb did. Three independent experiments were performed and similar results were obtained. These data showed that Myb TK-6 has transactivation activity as a Myb protein, and it is also significantly elevated compared to that of wild-type c-Myb.
Analysis of original patient's clinical materials
The TK-6 cell line was derived from the pleural effusion of a 30-year-old Japanese man with CML in T cell blast crisis, as previously described. 18 He had been diagnosed at T cell blast crisis phase of CML. Following chemotherapy, granulocytes still predominated in his bone marrow cells, and all the cells possessed Ph chromosomes. He then received allogeneic -mediated trans-activation of mim-1 promoter in NIH3T3 cells are indicated by luciferase activity. The amounts (g) of either transfected pcDNA (empty), pcDNA-c-myb or pcDNA-WTK-1 expression vectors and mim-1-luc reporter construct are also indicated. Each sample was assayed in duplicate dishes and individual group data were expressed as mean ± s.e. bone marrow transplantation (BMT) from an HLA-identical sister. Four weeks after BMT, the patient developed an extramedullary blastoma having T cell phenotype on his right eyelid. Subsequently, multiple blastomas and enlargement of the retroperitoneal lymph nodes appeared. Eight weeks after the signs of relapse, massive bilateral pleural effusion developed, and the patient died of respiratory failure. The tumor cells obtained from pleural effusion showed 6q− karyotype in addition to Ph chromosome abnormality. An autopsy was performed with the informed consent of his family. Primary specimens of neoplastic tissues had been obtained five times with the patient's informed consent, and genomic DNA was extracted and stored. To determine when the MYB gene abnormality appeared, both Southern blot analysis and MAS-PCR were performed ( Figure 5) .
In Southern blot analysis, digestion of genomic DNA from a control individual with EcoRI yielded four fragments, whereas an additional 6.3-kb rearranged band was detected with DNA from TK-6 cells and the two clinical specimens obtained at late phase from the original patient (lanes 5 and 6 in Figure 5a ). A rearranged band was also apparent in the same samples after SacI digestion (data not shown). These results suggest that TK-6 cells contain two different MYB alleles, one seemingly normal and the other rearranged, consistent with the results of karyotype analysis. 18 In order to directly demonstrate the presence of the rearranged c-MYB gene in these clinical samples, MAS-PCR analysis was performed. Mutant gene-specific PCR products were recognized in the last two specimens from the patient (lanes 5 and 6 in Figure 5b) , consistent with the results of Southern analysis. As a control, PCR was performed with primers spX and asp9A (Figure 3a) which amplify normal MYB intron 9 fragment. DNA from the control individual, TK-6 cells, and all specimens of the patient yielded an amplification product (data not shown).
Discussion
Although activated Myb proteins are known to be leukemogenic in chickens and mice, it has not been established whether abnormal Myb expression causes transformation in human cells. [11] [12] [13] [14] [15] [16] [17] 33 In this paper we examined the TK-6 cell line, which had been established in our laboratory from a patient with CML in T cell blast crisis, 18 for c-MYB gene abnormality. We found that TK-6 expresses c-MYB mRNA of a different size (2.0 kb) at a high level. Immunoblotting with anti-Myb antibody also revealed that TK-6 expresses an immunoreactive protein of 55 kDa, which is smaller than normal cMyb (75 kDa). By screening the TK-6 cDNA library with the human c-MYB probe and subsequent nucleotide sequencing, we found two species of c-MYB clones, WTK-1 and WTK-2. WTK-1 sequence is identical to that of normal c-MYB until the 3′ end of exon 9 and is followed by intron 9 sequence (9iX in Figure 3a ) and an unknown sequence (9rY in Figure  3a ). This unknown sequence showed 90% homology with human repetitive sequence, which suggests that the c-MYB gene is translocated to another part of the human genome. Since this unknown sequence should not be transcribed as a Myb protein (Figure 3a and b) , we did not examine its origin further. WTK-2 sequence is also identical until the 3′ part of exon 8 of the c-MYB gene and followed by the sequence of intron 8. WTK-2 appears to be essentially the same sequence as previously reported MYB , which had been isolated from cDNA libraries of two independent human leukemia samples. Since we found only one clone of WTK-2 species, while five were identified for WTK-1, and also no mRNA or protein corresponding to WTK-2 were detectable by Northern or immunoblot analyses, respectively, we concentrated our efforts on WTK-1.
When we rehybridized the same Northern blot membrane shown in Figure 1a with the 9iX-specific probe (Figure 3b) , the same 2.0 kb mRNA band was hybridized. The conceptual protein encoded by WTK-1 clone has a molecular mass of ෂ55 kDa, compatible with the size of the immunoreactive band seen in immunoblotting of TK-6 cell lysate with antiMyb antibody (Figure 1b) . Also, NIH3T3 cells transiently transfected with the mammalian expression vector which encodes ORF of WTK-1 expressed the immunoreactive protein of the same size as that seen in TK-6, by immunoblotting with anti-Myb antibody (data not shown). With all these data we concluded that WTK-1 represents the 2.0 kb c-MYB mRNA which encodes the 55 kDa Myb protein detected by immunoblotting. We designated the latter as Myb . Myb TK-6 is a c-Myb protein which lacks a large portion of C-terminal negative regulatory domain, as in the case with the two v-Myb proteins (Figure 3c ). It also has a very similar structure to some of the oncogenically activated forms of c-Myb found in murine leukemia cell line with retroviral integration 34 and to deletion mutants tested for transformation of chicken bone marrow cells. 10 Therefore it is reasonable to assume that Myb TK-6 is an activated form of c-Myb, although a previous report showed that carboxyterminal deletion of Myb is not highly transforming. 35 Since assessment of transformation activity is difficult for the MYB oncogene, as discussed earlier, we examined transactivation activity of Myb TK-6 by luciferase reporter assay in NIH3T3 fibroblasts. The expression vector encoding Myb TK-6 transactivated mim-1 gene promoter more effectively than that encoding wild-type human c-Myb. Thus we showed that Myb TK-6 is indeed functional as a Myb protein, and its transactivation activity, which is prerequisite to the transforming potential of Myb, 32 is higher compared to wildtype c-Myb.
When we examined the sequential specimens taken from the patient, from whom the TK-6 cell line had been established, the same mutation of the c-MYB gene seen in TK-6 was found in cells infiltrating the pleural cavity but not in cells from an earlier stage of the disease, even though the patient had been diagnosed at blast crisis of CML. 18 Therefore the acquisition of c-MYB gene rearrangement, and presumably expression of Myb , was not the genetic change that caused blast crisis in this patient. Rather, it might have contributed to further clonal evolution in T cell receptor gene-rearranged blast crisis cells of CML, 18 in the later stage of disease progression.
It is interesting that WTK-2, which is almost identical to the MYB HMYB-1 clone, was found as well as WTK-1. The MYB HMYB-1 cDNA was isolated as six of 21 MYB clones obtained from two human cDNA libraries, but the corresponding mRNA was not detected by Northern blot analysis. 30 The fact that the ratio of WTK-1 to WTK-2 clones was 5:1 in the present study may explain why we could not detect the protein encoded by WTK-2 by immunoblot analysis. It is possible that the mRNA corresponding to the WTK-2 clone is unstable. Because this type of c-MYB transcript has been detected in three different cDNA libraries from two laboratories, WTK-2, which can theoretically be transcribed either from the mutated or normal c-MYB allele in TK-6 (Figure 3a) , and MYB HMYB-1 may represent a minor variant of c-MYB transcript.
It is also interesting that we could not detect the normal c-MYB mRNA and protein in TK-6. Possible explanations may be as follows: (1) human c-MYB may be one of the genes that are expressed from one allele, and the mutation has occurred in the active allele in TK-6 cells; (2) there might be small alteration(s) in the seemingly normal allele that affects expression or stability of its mRNA; or (3) Myb TK-6 protein might, directly or indirectly affect c-MYB gene expression from the normal allele. 36 In this report, we described the expression of C-terminally truncated mutant c-Myb protein (Myb ), which has an elevated transactivation activity, in the human leukemia cell line TK-6. We also showed that the mutation responsible for Myb TK-6 expression had appeared in the late stage of disease progression in the original patient. Our result indicates that mutation of the c-MYB gene may contribute to the pathogenesis of human leukemias.
